Document is current
Any future updates will be listed below
-
Authors
Thomas, Tom
Friedrich, Matthias
Rich-Griffin, Charlotte
Pohin, Mathilde
Agarwal, Devika
Pakpoor, Julia
Lee, Carl
Tandon, Ruchi
Rendek, Aniko
Aschenbrenner, Dominik
Jainarayanan, Ashwin
Voda, Alexandru
Siu, Jacqueline H. Y.
Sanches-Peres, Raphael
Nee, Eloise
Sathananthan, Dharshan
Kotliar, Dylan
Todd, Peter
Kiourlappou, Maria https://orcid.org/0000-0003-1792-9206
Gartner, Lisa https://orcid.org/0000-0002-3273-651X
Ilott, Nicholas https://orcid.org/0000-0002-8432-8622
Issa, Fadi https://orcid.org/0000-0002-8279-7732
Hester, Joanna https://orcid.org/0000-0002-7466-3849
Turner, Jason https://orcid.org/0000-0002-5423-5302
Nayar, Saba https://orcid.org/0000-0002-4350-110X
Mackerodt, Jonas
Zhang, Fan
Jonsson, Anna
Brenner, Michael https://orcid.org/0000-0001-6202-8445
Raychaudhuri, Soumya https://orcid.org/0000-0002-1901-8265
Kulicke, Ruth
Ramsdell, Danielle
Stransky, Nicolas
Pagliarini, Ray
Bielecki, Piotr
Spies, Noah
Marsden, Brian https://orcid.org/0000-0002-1937-4091
Taylor, Stephen
Wagner, Allon https://orcid.org/0000-0001-5095-6009
Klenerman, Paul
Walsh, Alissa
Coles, Mark https://orcid.org/0000-0001-8079-9358
Jostins-Dean, Luke https://orcid.org/0000-0002-2475-3969
Powrie, Fiona M. https://orcid.org/0000-0003-3312-5929
Filer, Andrew https://orcid.org/0000-0001-8164-6249
Travis, Simon https://orcid.org/0000-0002-2690-4361
Uhlig, Holm H. https://orcid.org/0000-0002-6111-7355
Dendrou, Calliope A. https://orcid.org/0000-0003-1179-4021
Buckley, Christopher D. https://orcid.org/0000-0001-6924-6402
- License Information
-
More Information
Article History
Received: 27 June 2023
Accepted: 18 September 2024
First Online: 22 October 2024
Competing interests
: T.T. has received research support from Celsius Therapeutics and consulting fees from Abbvie and ZuraBio. D.A. is an employee and shareholder of Novartis Pharma AG. This article reflects the authors’ personal opinions and not that of their employer. R.P. is employed by Scorpion Therapeutics and holds equity in Celsius Therapeutics. F.M.P. received research support from Roche and Janssen and consulting fees from GSK, Novartis and Genentech. H.H.U. received research support or consultancy fees from Janssen, Eli Lilly, UCB Pharma, BMS/Celgene, MiroBio, Mestag and OMass. A.F. has consulted for Janssen and Sonoma and has received research funding from BMS, Roche, UCB, Nascient, Mestag, GSK and Janssen. S.T. has received grants and research support from AbbVie, Buhlmann, Celgene, Celsius, ECCO, Helmsley Trust, IOIBD, Janssen, Lilly, Pfizer, Takeda, UKIERI, Vifor and Norman Collisson Foundation; consulting fees from AbbVie, ai4gi, Allergan, Amgen, Apexian, Arcturis, Arena, AstraZeneca, Bioclinica, Biogen, BMS, Buhlmann, Celgene, ChemoCentryx, Clario, Cosmo, Dynavax, Endpoint Health, Enterome, EQrX, Equillium, Ferring, Galapagos, Genentech/Roche, Gilead, GSK, Immunocore, Indigo, Janssen, Lilly, Mestag, Microbiotica, Novartis, Pfizer, Phesi, Protagonist, Sanofi, Satisfai, Sensyne Health, Sorriso, Syndermix, Takeda, Theravance, Topivert, UCB Pharma, VHsquared and Vifor; and speaker fees from AbbVie, Amgen, Biogen, BMS, Falk, Ferring, Janssen, Lilly, Pfizer and Takeda. C.D.B., M.B., M.C. and S.R. are founders of Mestag Therapeutics. M.F. received research support and consulting fees from Eli Lilly and Ono Pharmaceuticals. The remaining authors declare no competing interests.
